Mckinley Capital Management LLC Bei Gene, Ltd. Transaction History

Mckinley Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$146.52 - $269.56 $2.27 Million - $4.17 Million	-15,472 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $48,220 - $75,531	-194 Reduced 1.24%	15,472 $4.19 Million
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $1.88 Million - $3.04 Million	-7,539 Reduced 32.49%	15,666 $5.69 Million
Q2 2021 Aug 03, 2021	SELL	$292.75 - $367.01 $728,947 - $913,854	-2,490 Reduced 9.69%	23,205 $7.96 Million
Q1 2021 Apr 21, 2021	SELL	$260.64 - $382.12 $15,899 - $23,309	-61 Reduced 0.24%	25,695 $8.94 Million

Q4 2020 Feb 10, 2021	SELL	$221.31 - $316.61 $28,548 - $40,842	-129 Reduced 0.5%	25,756 $6.66 Million
Q3 2020 Nov 02, 2020	SELL	$189.18 - $286.44 $727,397 - $1.1 Million	-3,845 Reduced 12.93%	25,885 $7.41 Million
Q2 2020 Jul 27, 2020	SELL	$123.9 - $195.41 $70,127 - $110,602	-566 Reduced 1.87%	29,730 $5.6 Million
Q1 2020 May 05, 2020	BUY	$121.84 - $173.19 $3.12 Million - $4.44 Million	25,617 Added 547.49%	30,296 $3.73 Million
Q4 2019 Jan 23, 2020	SELL	$115.78 - $208.34 $31,376 - $56,460	-271 Reduced 5.47%	4,679 $775,000
Q3 2019 Nov 12, 2019	BUY	$120.61 - $148.29 $597,019 - $734,035	4,950 New	4,950 $607,000

216

45.1M

76.5K

72.3K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $14.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Mckinley Capital Management LLC , based on Form 13F filings with the SEC.

Stay updated on Mckinley Capital Management LLC with notifications on news.